← Leaderboards
Kim Lewis
Northeastern University
$35,546,714
Attributed
$42,006,481
Total exposure
19
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$50,883,475 · 20
By mechanism
R01$36,976,224 · 14
P01$12,220,296 · 3
R21$1,686,955 · 3
Top collaborators
- Linden T Hu11 shared
- Richard Edward Lee5 shared
- Johan Paulsson4 shared
Others in their field
Top investigators on “Antibiotics”
- Laurence H Baker · University Of Michigan At Ann Arbor$52,071,546
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,812,829
- Taha E Taha · Johns Hopkins University$37,363,329
- Urs Ochsner · Crestone, Inc.$36,950,837
- Deborah T Hung · Massachusetts General Hospital$36,871,538
- Ryan Cirz · Revagenix, Inc.$35,410,554
Research focus
AntibioticsPathogenInfectionResistanceEscherichia ColiCellsLeadAntimicrobialIn VitroBacteriaBaseMutantIn VivoGrowthOrganismDoseStaphylococcus AureusPropertyDrug DevelopmentDrug ResistanceCytotoxicityMicrobial BiofilmsSourceStructure
Grant awards (91)
Discovering antimicrobials acting against MDR pathogens$1,095,522
R01 · FY2025 · AI · contact PI
Evaluating darobactins as antimicrobial agents$595,176
R01 · FY2025 · AI · contact PI
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi$397,721
R01 · FY2025 · AI
Discovering antimicrobials acting against MDR pathogens$1,095,522
R01 · FY2024 · AI · contact PI
Evaluating darobactins as antimicrobial agents$595,176
R01 · FY2024 · AI · contact PI
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi$348,435
R01 · FY2024 · AI
Discovering antimicrobials acting against MDR pathogens$1,141,522
R01 · FY2023 · AI · contact PI
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi$754,130
R01 · FY2023 · AI
Evaluating darobactins as antimicrobial agents$595,176
R01 · FY2023 · AI · contact PI
Antibiotic discovery from environmental microorganisms of Brazil$157,000
R01 · FY2023 · AI · contact PI
Discovering antimicrobials acting against MDR pathogens$1,136,522
R01 · FY2022 · AI · contact PI
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi$761,873
R01 · FY2022 · AI
A general mechanism of persister formation$682,044
R01 · FY2022 · AI · contact PI
Evaluating darobactins as antimicrobial agents$595,176
R01 · FY2022 · AI · contact PI
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi$218,868
R01 · FY2022 · AI
Antibiotic discovery from environmental microorganisms of Brazil$157,000
R01 · FY2022 · AI · contact PI
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi$720,419
R01 · FY2021 · AI
A general mechanism of persister formation$682,044
R01 · FY2021 · AI · contact PI
Evaluating darobactins as antimicrobial agents$620,176
R01 · FY2021 · AI · contact PI
Antibiotic discovery from environmental microorganisms of Brazil$157,000
R01 · FY2021 · AI · contact PI
Resolving the bottleneck in antibiotic discovery$1,807,186
P01 · FY2020 · AI · contact PI
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi$743,299
R01 · FY2020 · AI
A general mechanism of persister formation$682,044
R01 · FY2020 · AI · contact PI
Antimicrobial evaluation and development$664,543
P01 · FY2020 · AI · contact PI
Antibiotic discovery from environmental microorganisms of Brazil$157,000
R01 · FY2020 · AI · contact PI
Admin Core$84,090
P01 · FY2020 · AI · contact PI
Resolving the bottleneck in antibiotic discovery$1,726,091
P01 · FY2019 · AI · contact PI
A general mechanism of persister formation$857,014
R01 · FY2019 · AI · contact PI
Antimicrobial evaluation and development$625,411
P01 · FY2019 · AI · contact PI
Persister cells of Borrelia burgdorferi$572,380
R01 · FY2019 · AI · contact PI
Admin Core$79,224
P01 · FY2019 · AI · contact PI
Resolving the bottleneck in antibiotic discovery$1,738,405
P01 · FY2018 · AI · contact PI
Developing therapeutics to treat chronic infections$755,183
R01 · FY2018 · AI
Antimicrobial evaluation and development$605,549
P01 · FY2018 · AI · contact PI
Persister cells of Borrelia burgdorferi$572,380
R01 · FY2018 · AI · contact PI
Admin Core$80,705
P01 · FY2018 · AI · contact PI
Resolving the bottleneck in antibiotic discovery$1,748,006
P01 · FY2017 · AI · contact PI
Developing therapeutics to treat chronic infections$749,804
R01 · FY2017 · AI
Antimicrobial evaluation and development$603,672
P01 · FY2017 · AI · contact PI
Persister cells of Borrelia burgdorferi$572,380
R01 · FY2017 · AI · contact PI
Admin Core$82,208
P01 · FY2017 · AI · contact PI
Resolving the bottleneck in antibiotic discovery$1,857,306
P01 · FY2016 · AI · contact PI
Developing therapeutics to treat chronic infections$758,554
R01 · FY2016 · AI
Persister cells of Borrelia burgdorferi$586,005
R01 · FY2016 · AI · contact PI
Antimicrobial evaluation and development$458,098
P01 · FY2016 · AI · contact PI
Admin Core$59,802
P01 · FY2016 · AI · contact PI
Developing therapeutics to treat chronic infections$758,554
R01 · FY2015 · AI
Developing therapeutics to treat chronic infections$746,404
R01 · FY2014 · AI
Super-persistent cells and the paradox of untreatable infections$1,036,169
R01 · FY2013 · AI · contact PI
A synergy-based therapy against C. difficile$499,908
R01 · FY2013 · AI · contact PI
Super-persistent cells and the paradox of untreatable infections$1,068,216
R01 · FY2012 · AI · contact PI
A synergy-based therapy against C. difficile$531,817
R01 · FY2012 · AI · contact PI
Culturing Uncultivatable Gut Microorganisms$390,198
R01 · FY2012 · HG · contact PI
A High-Throughput Screen for Specific Anti-M. tuberculosis Compounds$384,863
R01 · FY2012 · AI · contact PI
Super-persistent cells and the paradox of untreatable infections$1,072,430
R01 · FY2011 · AI · contact PI
A synergy-based therapy against C. difficile$529,393
R01 · FY2011 · AI · contact PI
Culturing Uncultivatable Gut Microorganisms$390,198
R01 · FY2011 · HG · contact PI
A High-Throughput Screen for Specific Anti-M. tuberculosis Compounds$384,863
R01 · FY2011 · AI · contact PI
A GENOMICS APPROACH TO DRUG TOLERANCE$379,880
R01 · FY2011 · GM · contact PI
Culturing Uncultivatable Gut Microorganisms$174,715
R01 · FY2011 · HG · contact PI
Super-persistent cells and the paradox of untreatable infections$1,050,887
R01 · FY2010 · AI · contact PI
A synergy-based therapy against C. difficile$459,800
R01 · FY2010 · AI · contact PI
Culturing Uncultivatable Gut Microorganisms$409,293
R01 · FY2010 · HG · contact PI
A High-Throughput Screen for Specific Anti-M. tuberculosis Compounds$388,958
R01 · FY2010 · AI · contact PI
A GENOMICS APPROACH TO DRUG TOLERANCE$383,775
R01 · FY2010 · GM · contact PI
Super-persistent cells and the paradox of untreatable infections$1,008,498
R01 · FY2009 · AI · contact PI
A Genomics Approach to Drug Tolerance$641,368
R01 · FY2009 · GM · contact PI
A synergy-based therapy against C. difficile$544,730
R01 · FY2009 · AI · contact PI
SCREEN DEVELOPMENT FOR ANTIMICROBIAL PRODRUGS$385,043
R01 · FY2009 · AI · contact PI
A GENOMICS APPROACH TO DRUG TOLERANCE$376,419
R01 · FY2009 · GM · contact PI
SCREEN DEVELOPMENT FOR ANTIMICROBIAL PRODRUGS$385,043
R01 · FY2008 · AI · contact PI
A GENOMICS APPROACH TO DRUG TOLERANCE$366,100
R01 · FY2008 · GM · contact PI
The Nature of Bacterial Uncultivability$192,521
R21 · FY2008 · AI · contact PI
SCREEN DEVELOPMENT FOR ANTIMICROBIAL PRODRUGS$392,500
R01 · FY2007 · AI · contact PI
A GENOMICS APPROACH TO BIOFILMS$260,513
R01 · FY2007 · GM · contact PI
The Nature of Bacterial Uncultivability$235,500
R21 · FY2007 · AI · contact PI
A GENOMICS APPROACH TO BIOFILMS$268,294
R01 · FY2006 · GM · contact PI
BIODEFENSE THERAPEUTICS FROM UNCULTURED MICROORGANISMS$315,000
R21 · FY2005 · AI
NOVEL METHODS FOR DISCOVERY OF ANTI-MICROBIALS$314,200
R21 · FY2005 · AI
A GENOMICS APPROACH TO BIOFILMS$274,925
R01 · FY2005 · GM
BIODEFENSE THERAPEUTICS FROM UNCULTURED MICROORGANISMS$315,000
R21 · FY2004 · AI
NOVEL METHODS FOR DISCOVERY OF ANTI-MICROBIALS$314,734
R21 · FY2004 · AI
A GENOMICS APPROACH TO BIOFILMS$275,391
R01 · FY2004 · GM
A GENOMICS APPROACH TO P. AERUGINOSA BIOFILMS$148,018
R01 · FY2003 · GM
A GENOMICS APPROACH TO P. AERUGINOSA BIOFILMS$297,980
R01 · FY2002 · GM
NATURAL SUBSTRATES AND INHIBITORS OF MICROBIAL MDR PUMPS$118,875
R01 · FY2002 · GM
A GENOMICS APPROACH TO P. AERUGINOSA BIOFILMS$297,980
R01 · FY2001 · GM
NATURAL SUBSTRATES AND INHIBITORS OF MICROBIAL MDR PUMPS$100,278
R01 · FY2001 · GM
NATURAL SUBSTRATES AND INHIBITORS OF MICROBIAL MDR PUMPS$17,733
R01 · FY2001 · GM
A GENOMICS APPROACH TO P. AERUGINOSA BIOFILMS$249,892
R01 · FY2000 · GM
A GENOMICS APPROACH TO P. AERUGINOSA BIOFILMS$13,778
R01 · FY2000 · GM